Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 17/20 | 0.51 |
| ▸ | PTGIS | Q16647 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12330065 | 0.88 | TBXA2R (0.56) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL16290098 | 0.88 | TBXA2R (0.56) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL16290093 | 0.88 | TBXA2R (0.56) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12330021 | 0.87 | TBXA2R (0.70) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL10544860 | 0.87 | TBXA2R (0.55) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12444484 | 0.86 | TBXA2R (0.59) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL10540544 | 0.84 | TBXAS1 (0.65) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL2934089 | 0.84 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL2941082 | 0.84 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12329914 | 0.84 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150111-B1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | disclosed |
| EP-1976509-B1 | PPAR MODULATORS | EVOLVA SA (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-20140288110-A1 | PPAR MODULATORS | EVOLVA SA (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20130267561-A1 | Substituted 1,3-Dioxanes Useful as PPAR Modulators | EVOLVA SA (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8536196-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536196-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2013-09-17 | — | — | US | disclosed |
| EP-2363127-A1 | PPAR Modulators | Evolva SA (CH) | 2011-09-07 | — | — | EP | disclosed |
| US-20110178112-A1 | PPAR Modulators | EVOLVA SA (CH) | 2011-07-21 | — | — | US | disclosed |
| WO-2011057262-A2 | TREATMENT OF INFECTIONS WITH TP RECEPTOR ANTAGONISTS | EVOLVA INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2008089461-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007138485-A2 | PPAR MODULATORS | EVOLVA SA (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178112-A1 | PPAR Modulators | PPARD, PPARG, PPARA | TBXA2R 127/4885CYP1A2 1093/4885CYP3A4 866/4885 |
| US-20140288110-A1 | PPAR MODULATORS | PPARD, PPARG, PPARA | TBXA2R 127/4885CYP1A2 1093/4885CYP3A4 866/4885 |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | PPARD, PPARG, PPARA | TBXA2R 48/4885CYP1A2 592/4885CYP3A4 540/4885 |
| US-20130267561-A1 | Substituted 1,3-Dioxanes Useful as PPAR Modulators | PPARD, PPARG, PPARA | TBXA2R 48/4885CYP1A2 592/4885CYP3A4 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.